EA201691231A1 - Фармацевтические лекарственные формы - Google Patents

Фармацевтические лекарственные формы

Info

Publication number
EA201691231A1
EA201691231A1 EA201691231A EA201691231A EA201691231A1 EA 201691231 A1 EA201691231 A1 EA 201691231A1 EA 201691231 A EA201691231 A EA 201691231A EA 201691231 A EA201691231 A EA 201691231A EA 201691231 A1 EA201691231 A1 EA 201691231A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medicine forms
pharmaceutical medicine
dosage forms
relates
pharmaceutical dosage
Prior art date
Application number
EA201691231A
Other languages
English (en)
Other versions
EA036288B1 (ru
Inventor
Сьюзи Рибейро
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201691231A1 publication Critical patent/EA201691231A1/ru
Publication of EA036288B1 publication Critical patent/EA036288B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к твердым фармацевтическим лекарственным формам, включающим в себя лекарственное вещество 3-(2,6-дихлор-3,5-диметоксифенил)-1-{6-[4-(4-этилпиперазин-1-ил)фениламин]пиримидин-4-ил}-1-метилмочевину или любую его фармацевтически приемлемую соль. Оно также относится к способам получения указываемых твердых фармацевтических лекарственных форм.
EA201691231A 2013-12-13 2014-12-11 Фармацевтические лекарственные формы EA036288B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (en) 2013-12-13 2014-12-11 Pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
EA201691231A1 true EA201691231A1 (ru) 2016-10-31
EA036288B1 EA036288B1 (ru) 2020-10-22

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691231A EA036288B1 (ru) 2013-12-13 2014-12-11 Фармацевтические лекарственные формы

Country Status (34)

Country Link
US (3) US10278969B2 (ru)
EP (2) EP3079667B1 (ru)
JP (2) JP6522619B2 (ru)
KR (1) KR102349893B1 (ru)
CN (2) CN105813635A (ru)
AR (1) AR098716A1 (ru)
AU (1) AU2014362999B2 (ru)
CA (1) CA2930055C (ru)
CL (1) CL2016001436A1 (ru)
CY (1) CY1122063T1 (ru)
DK (1) DK3079667T3 (ru)
EA (1) EA036288B1 (ru)
EC (1) ECSP16060194A (ru)
ES (1) ES2745983T3 (ru)
HK (1) HK1223833A1 (ru)
HR (1) HRP20191691T1 (ru)
HU (1) HUE045156T2 (ru)
IL (1) IL245705B (ru)
LT (1) LT3079667T (ru)
MA (1) MA39175A1 (ru)
MX (1) MX2016007652A (ru)
MY (1) MY194303A (ru)
NZ (2) NZ719865A (ru)
PE (1) PE20160851A1 (ru)
PH (1) PH12016501039A1 (ru)
PL (1) PL3079667T3 (ru)
PT (1) PT3079667T (ru)
RS (1) RS59270B1 (ru)
SG (1) SG10202104627UA (ru)
SI (1) SI3079667T1 (ru)
TN (1) TN2016000207A1 (ru)
TW (2) TWI800759B (ru)
WO (1) WO2015087283A1 (ru)
ZA (1) ZA201603064B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098716A1 (es) 2013-12-13 2016-06-08 Novartis Ag Formas de dosificación farmacéuticas
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
JP2024500404A (ja) * 2020-12-18 2024-01-09 キューイーディー セラピューティクス，インコーポレイテッド 軟骨形成不全症の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
KR101406956B1 (ko) 2005-12-21 2014-06-13 노파르티스 아게 Ｆｇｆ 억제제로서의 피리미디닐 아릴 우레아 유도체
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2726076B1 (en) 2011-07-01 2016-10-12 Novartis AG Combination therapy
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AR098716A1 (es) 2013-12-13 2016-06-08 Novartis Ag Formas de dosificación farmacéuticas
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
PL3079667T3 (pl) 2020-02-28
ZA201603064B (en) 2017-07-26
EP3079667B1 (en) 2019-06-26
HRP20191691T1 (hr) 2019-12-27
LT3079667T (lt) 2019-09-10
TN2016000207A1 (en) 2017-10-06
CA2930055C (en) 2023-07-04
PH12016501039A1 (en) 2016-07-04
AR098716A1 (es) 2016-06-08
US11160804B2 (en) 2021-11-02
WO2015087283A1 (en) 2015-06-18
NZ719865A (en) 2022-07-29
MX2016007652A (es) 2016-10-13
PT3079667T (pt) 2019-10-10
JP6522619B2 (ja) 2019-05-29
TW202128137A (zh) 2021-08-01
EP3597179A1 (en) 2020-01-22
CA2930055A1 (en) 2015-06-18
SI3079667T1 (sl) 2019-10-30
US10278969B2 (en) 2019-05-07
US20220265651A1 (en) 2022-08-25
SG10202104627UA (en) 2021-06-29
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
DK3079667T3 (da) 2019-09-09
CL2016001436A1 (es) 2017-02-10
RS59270B1 (sr) 2019-10-31
NZ760002A (en) 2022-07-29
ES2745983T3 (es) 2020-03-04
JP2019142927A (ja) 2019-08-29
AU2014362999B2 (en) 2017-10-12
AU2014362999A1 (en) 2016-05-26
JP2017502941A (ja) 2017-01-26
EA036288B1 (ru) 2020-10-22
HK1223833A1 (zh) 2017-08-11
EP3079667A1 (en) 2016-10-19
IL245705A0 (en) 2016-07-31
JP6804585B2 (ja) 2020-12-23
TWI721938B (zh) 2021-03-21
HUE045156T2 (hu) 2019-12-30
MY194303A (en) 2022-11-27
IL245705B (en) 2021-05-31
TWI800759B (zh) 2023-05-01
EP3597179B1 (en) 2024-04-03
US20170007602A1 (en) 2017-01-12
CY1122063T1 (el) 2020-11-25
ECSP16060194A (es) 2019-07-31
TW201605494A (zh) 2016-02-16
KR102349893B1 (ko) 2022-01-10
MA39175A1 (fr) 2017-10-31
CN116942629A (zh) 2023-10-27
KR20160096093A (ko) 2016-08-12
CN105813635A (zh) 2016-07-27

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
NZ725966A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
PH12015500823A1 (en) Modified release formulations for oprozomib
CY1122063T1 (el) Φαρμακοτεχνικες δοσολογικες μορφες
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2017012022A (es) Compuestos organicos.